"Where Everyone Has an MBA"
Tel: (612) 246-4616
Frequently Asked Questions
- Frequently Asked Questions
- User Testimonials
Advaxis, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Advaxis, Inc.
Analysis: Positioning to Benefit within Advaxis, e.l.f. Beauty, Heron Therapeutics, PVH, Energy Recovery, and A. O. Smith — Research Highlights Growth, Revenue, and Consolidated Results
- May 14th, 2018 6:10 am
Recently Presented Preclinical Data Show Potential for ADXS-NEO as Anti-Cancer Immunotherapy Agent
- May 11th, 2018 6:00 am
Advaxis Announces Executive Leadership Changes
- Apr 23rd, 2018 6:00 am
Preclinical Data Highlighting ADXS-Hot as Immunotherapy with Potential to Target Hotspot Cancer Mutations across Multiple Cancer Types Presented in Poster Discussion at The AACR Annual Meeting
- Apr 17th, 2018 6:00 am
What Is The Future Prospect For Healthcare And Advaxis Inc (NASDAQ:ADXS)?
- Apr 3rd, 2018 2:39 pm
Data Highlighting Advaxis’ ADXS-PSA Accepted as Poster Presentation at the American Society of Clinical Oncology Annual Meeting
- Apr 2nd, 2018 6:00 am
Wired News – Recro Pharma Publishes Data from Phase-III Trial for IV Meloxicam
- Mar 29th, 2018 5:00 am
Advaxis Inc (NASDAQ:ADXS): Does The -36.80% Earnings Drop Reflect A Longer Term Trend?
- Mar 26th, 2018 4:28 pm
Advaxis Announces Four Poster Presentations Highlighting Lm-based Antigen Delivery Technology at AACR 2018
- Mar 26th, 2018 6:00 am
Edited Transcript of ADXS earnings conference call or presentation 12-Mar-18 8:30pm GMT
- Mar 13th, 2018 7:05 am
Advaxis to Present at Upcoming March Conferences
- Mar 13th, 2018 6:00 am
Advaxis shares drop as cancer-drug study on hold after death
- Mar 12th, 2018 3:19 pm
Advaxis reports 1Q loss
- Mar 12th, 2018 2:31 pm
Advaxis Reports Fiscal 2018 First Quarter Financial Results and Announces Clinical Hold in Axalimogene Filolisbac Phase 1/2 Combination Study with AstraZeneca’s IMFINZI® (Durvalumab)
- Mar 12th, 2018 2:05 pm
Should You Have Advaxis Inc’s (NASDAQ:ADXS) In Your Portfolio?
- Mar 12th, 2018 6:54 am
How Do Analysts See Advaxis Inc (NASDAQ:ADXS) Performing Over The Next Few Years?
- Mar 9th, 2018 9:06 am
Advaxis to Host Business Update and First Quarter 2018 Financial Results Conference Call on March 12, 2018
- Mar 9th, 2018 6:00 am
Advaxis Inc (NASDAQ:ADXS): Is Breakeven Near?
- Mar 8th, 2018 8:27 am
Advaxis looks to raise $20 million via share offering
- Feb 22nd, 2018 11:05 am
Advaxis Prices $20.0 Million Public Offering of Common Stock
- Feb 22nd, 2018 7:15 am
Frequently Asked Questions
Terms and Conditions
Copyright © 2018 VentureLine
Website developed by Digital Solutions